|Bid||10,340.00 x 0|
|Ask||11,660.00 x 0|
|Day's range||10,557.10 - 10,700.00|
|52-week range||8,214.00 - 11,886.00|
|Beta (5Y monthly)||0.16|
|PE ratio (TTM)||48.72|
|Forward dividend & yield||2.22 (2.21%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
Sanofi (NASDAQ: SNY) and AstraZeneca's (NASDAQ: AZN) application for the respiratory syncytial virus (RSV) vaccine candidate called nirsevimab was recently accepted for review by the U.S. Food and Drug Administration (FDA) as a protective option for all infants. Nirsevimab is known by the trade name Beyfortus in the European Union and the United Kingdom, and the FDA expects to make an approval decision on the RSV vaccine in the third quarter of this year.
Astrazeneca (AZN) closed the most recent trading day at $65.53, moving -0.7% from the previous trading session.
As far as life goals go, defeating cancer might be deemed one of the more fanciful.